approval
saveBYOOVIZ (RANIBIZUMAB-NUNA) — FDA approval
community read0 votes
Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 7
- approvalBYOOVIZ (RANIBIZUMAB-NUNA) — FDA approvalMar 30, 2026 · 188d ago
- approvalBYOOVIZ (RANIBIZUMAB-NUNA) — FDA approvalAug 15, 2025 · 415d ago
- approvalBYOOVIZ (RANIBIZUMAB-NUNA) — FDA approvalOct 3, 2023 · 1097d ago
- approvalBYOOVIZ (RANIBIZUMAB-NUNA) — FDA approvalJun 16, 2023 · 1206d ago
- approvalBYOOVIZ (RANIBIZUMAB-NUNA) — FDA approvalAug 15, 2022 · 1511d ago
- approvalBYOOVIZ (RANIBIZUMAB-NUNA) — FDA approvalJun 9, 2022 · 1578d ago
- approvalBYOOVIZ (RANIBIZUMAB-NUNA) — FDA approvalSep 17, 2021 · 1843d ago
same company · ±60 days · 6
- approvalEPYSQLI: EPYSQLI (ECULIZUMAB-AAGH) — FDA approvalNov 10, 2025
- approvalPYZCHIVA: PYZCHIVA (USTEKINUMAB-TTWE) — FDA approvalNov 18, 2025
- approvalPYZCHIVA: PYZCHIVA (USTEKINUMAB-TTWE) — FDA approvalNov 18, 2025
- recallSamsung Bioepis Co., Ltd. recall (Cls II)Nov 5, 2025
- approvaldenosumab biosimilar: DENOSUMAB-DSSB — FDA approvalOct 29, 2025
- approvalinfliximab biosimilar: RENFLEXIS (INFLIXIMAB-ABDA) — FDA approvalOct 28, 2025
comments(0)
5-min edit window · permanent after that